These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 25503302)

  • 41. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
    Blackhall FH; O'brien M; Schmid P; Nicolson M; Taylor P; Milenkova T; Kennedy SJ; Thatcher N
    J Thorac Oncol; 2010 Aug; 5(8):1285-8. PubMed ID: 20661087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
    Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
    J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
    Galanis E; Anderson SK; Twohy EL; Carrero XW; Dixon JG; Tran DD; Jeyapalan SA; Anderson DM; Kaufmann TJ; Feathers RW; Giannini C; Buckner JC; Anastasiadis PZ; Schiff D
    Cancer; 2019 Nov; 125(21):3790-3800. PubMed ID: 31290996
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor.
    Glod J; Arnaldez FI; Wiener L; Spencer M; Killian JK; Meltzer P; Dombi E; Derse-Anthony C; Derdak J; Srinivasan R; Linehan WM; Miettinen M; Steinberg SM; Helman L; Widemann BC
    Clin Cancer Res; 2019 Nov; 25(21):6302-6308. PubMed ID: 31439578
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.
    Reardon DA; Cloughesy T; Rich J; Alfred Yung WK; Yung L; DiLea C; Huang J; Dugan M; Mietlowski W; Maes A; Conrad C
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):281-7. PubMed ID: 21984222
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
    Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman S
    Neuro Oncol; 2015 Oct; 17(10):1386-92. PubMed ID: 26008604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
    Reardon DA; Vredenburgh JJ; Desjardins A; Peters KB; Sathornsumetee S; Threatt S; Sampson JH; Herndon JE; Coan A; McSherry F; Rich JN; McLendon RE; Zhang S; Friedman HS
    J Neurooncol; 2012 Jul; 108(3):499-506. PubMed ID: 22407177
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme.
    Grossmann KF; Colman H; Akerley WA; Glantz M; Matsuoko Y; Beelen AP; Yu M; De Groot JF; Aiken RD; Olson JJ; Evans BA; Jensen RL
    J Neurooncol; 2012 Nov; 110(2):257-64. PubMed ID: 22932984
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
    Yust-Katz S; Liu D; Yuan Y; Liu V; Kang S; Groves M; Puduvalli V; Levin V; Conrad C; Colman H; Hsu S; Yung WK; Gilbert MR
    Cancer; 2013 Aug; 119(15):2747-53. PubMed ID: 23633392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
    Kiura K; Nakagawa K; Shinkai T; Eguchi K; Ohe Y; Yamamoto N; Tsuboi M; Yokota S; Seto T; Jiang H; Nishio K; Saijo N; Fukuoka M
    J Thorac Oncol; 2008 Apr; 3(4):386-93. PubMed ID: 18379357
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.
    Reardon DA; Conrad CA; Cloughesy T; Prados MD; Friedman HS; Aldape KD; Mischel P; Xia J; DiLea C; Huang J; Mietlowski W; Dugan M; Chen W; Yung WK
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1507-18. PubMed ID: 22392572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
    Karavasilis V; Kotoula V; Pentheroudakis G; Televantou D; Lambaki S; Chrisafi S; Bobos M; Fountzilas G
    J Neurol; 2013 Jun; 260(6):1469-80. PubMed ID: 23292205
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
    Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
    J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
    Kaley TJ; Panageas KS; Pentsova EI; Mellinghoff IK; Nolan C; Gavrilovic I; DeAngelis LM; Abrey LE; Holland EC; Omuro A; Lacouture ME; Ludwig E; Lassman AB
    Ann Clin Transl Neurol; 2020 Apr; 7(4):429-436. PubMed ID: 32293798
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
    Prados MD; Yung WK; Wen PY; Junck L; Cloughesy T; Fink K; Chang S; Robins HI; Dancey J; Kuhn J
    Cancer Chemother Pharmacol; 2008 May; 61(6):1059-67. PubMed ID: 17694310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.
    Odia Y; Sul J; Shih JH; Kreisl TN; Butman JA; Iwamoto FM; Fine HA
    CNS Oncol; 2016; 5(2):59-67. PubMed ID: 26860632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
    Powles T; Foreshew SJ; Shamash J; Sarwar N; Crabb S; Sahdev A; Nixon J; Lim L; Pungaliya A; Foreshaw A; Davies R; Greenwood M; Wilson P; Pacey S; Galazi M; Jones R; Chowdhury S
    Eur J Cancer; 2014 Aug; 50(12):2057-64. PubMed ID: 24908540
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).
    Aisner J; Manola JB; Dakhil SR; Stella PJ; Sovak MA; Schiller JH
    J Thorac Oncol; 2013 Aug; 8(8):1075-83. PubMed ID: 23689430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.